Gene · 5818
Papers3,675
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,675
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study. | Front Pharmacol | 2026 | 42769117 | PubTator, text mining | PubMed |
| Sphingosine 1-phosphate signalling contributes to transforming growth factor-β1-induced myofibroblast differentiation in oral cancer. | PeerJ | 2026 | 42730290 | PubTator, text mining | PubMed |
| Microbial adhesion promotes Piezo1 activation to initiate innate immunity. | Nat Immunol | 2026 | 42717253 | PubTator, text mining | PubMed |
| The TRIM-cancer paradox: BCG as a programmable vaccine platform and a mechanistic probe for rational immunotherapy design. | Front Immunol | 2026 | 42683335 | PubTator, text mining | PubMed |
| Rare missense variants in NECTIN1 alter local protein structure and may contribute to non-syndromic cleft lip with or without palate. | Front Genet | 2026 | 42657432 | PubTator, text mining | PubMed |
| Early-onset respiratory adverse event patterns of omalizumab in pediatric patients: an age-stratified FAERS pharmacovigilance study. | Acta Clin Belg | 2026 | 42647060 | PubTator, text mining | PubMed |
| Safety Comparison of Acetylcholinesterase Inhibitors Using FAERS Spontaneous-Reporting Data: Drug-Specific Reporting Signals and Time-to-Onset Dynamics. | Curr Alzheimer Res | 2026 | 42634550 | PubTator, text mining | PubMed |
| Conjugated NOD1-Centered Dual Agonists Exhibit Modest In Vitro Immunomodulation but Potent In Vivo Adjuvanticity. | ACS Bio Med Chem Au | 2026 | 42630639 | PubTator, text mining | PubMed |
| Emergence and molecular characterization of bovine alphaherpesvirus 1 subtype 1.1 in China, with in vivo characterization in a rabbit model. | Microb Pathog | 2026 | 42628886 | PubTator, text mining | PubMed |
| Intestinal Flora and Myocarditis: Potential Mechanisms and Therapeutic Strategies Affecting Disease Progression and Cardiac Function. | Int J Mol Sci | 2026 | 42589363 | PubTator, text mining | PubMed |
| Innate immunity: current understandings and future perspectives. | Signal Transduct Target Ther | 2026 | 42581325 | PubTator, text mining | PubMed |
| Unveiling the sensing potential of innate lymphoid cells. | Commun Biol | 2026 | 42477434 | PubTator, text mining | PubMed |
| Nectin4 restricts pseudorabies virus infection by blocking gD-Nectin1 interaction. | J Virol | 2026 | 42474184 | PubTator, text mining | PubMed |
| Bioinformatics Analysis of the miR-15 Family Members and Their Potential Target Genes in Breast Cancer Progression. | Adv Biomed Res | 2026 | 42427417 | PubTator, text mining | PubMed |
| Circadian-guided oncolytic virotherapy for glioblastoma. | J Neurovirol | 2026 | 42406201 | PubTator, text mining | PubMed |
| TLR4 expression and its immunopathogenic role in inflammatory radicular cysts: a clinicopathological study. | Rom J Morphol Embryol | 2026 | 42402744 | PubTator, text mining | PubMed |
| Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS database. | Front Antibiot | 2026 | 42327540 | PubTator, text mining | PubMed |
| IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma. | Nat Commun | 2026 | 42310302 | PubTator, text mining | PubMed |
| The role of the intratumoral microbiota in breast cancer metastasis and immune regulation: mechanisms and therapeutic implications. | Front Immunol | 2026 | 42292442 | PubTator, text mining | PubMed |
| TLR7 polymorphisms are associated with COVID-19 susceptibility and severity. | Front Immunol | 2026 | 42292350 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5818/papers